Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Conditions

• Age Range ≥16 Years, Gender Unlimited
• Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma
• Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed
• At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma
• ECOG Physical Status Score is 0-3
• The Researchers Judged That Life Expectancy Was at Least Three Months
• Understand and Voluntarily Sign Written Informed Consent

Interventions

• DRUG: TR2-ICE

Sponsor

Affiliated Hospital to Academy of Military Medical Sciences

Collaborators

• [object Object]
• [object Object]